North Dakota Technology Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on North Dakota Technology Review.

Press releases published on June 1, 2026

Jun. 1, 2026

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Indeterminate GlobeNewswire

Jun. 1, 2026

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

SPARC AI Strengthens Board with Appointment of Don Hilton as Independent Non-Executive Director

Indeterminate GlobeNewswire

Jun. 1, 2026

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

House of Doge and Paxos Partner to Expand Global Access to Dogecoin

Indeterminate GlobeNewswire

Jun. 1, 2026

House of Doge and Paxos Partner to Expand Global Access to Dogecoin

Indeterminate GlobeNewswire

Jun. 1, 2026

Genius Group Announces Investor Call to Discuss AI Treasury and AGI Infinity Portfolio

Indeterminate GlobeNewswire

Jun. 1, 2026

Athennian Launches Purpose-Built AI-Governed Platform for Private Markets

Indeterminate GlobeNewswire

Jun. 1, 2026

Rapid7 Appoints Wael Mohamed Chief Executive Officer; Corey Thomas to Become Executive Chairman

Indeterminate GlobeNewswire

Jun. 1, 2026

Generali Expands Deployment of Intermap's AI-Enabled Risk Platform in Central and Eastern Europe

Indeterminate GlobeNewswire

Jun. 1, 2026

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

OptimizeRx to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Jun. 1, 2026

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

Indeterminate GlobeNewswire

Jun. 1, 2026

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Indeterminate GlobeNewswire

Jun. 1, 2026

Cognition Therapeutics Participating in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Jun. 1, 2026

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

Indeterminate GlobeNewswire

Jun. 1, 2026

BriaCell Presents Positive Clinical Data at ASCO 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Indeterminate GlobeNewswire

Jun. 1, 2026

SAIC Announces First Quarter of Fiscal Year 2027 Results

Indeterminate GlobeNewswire

Jun. 1, 2026

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Indeterminate GlobeNewswire